Clascoterone (Breezula) for androgenetic alopecia - mechanism, evidence, comparison with Finasteride and who should use it. Dr. Arslan Musbeh.
How it works
Clascoterone is a topical competitive antagonist of androgen receptors at the hair follicle. Unlike Finasteride which reduces systemic DHT production, Clascoterone blocks DHT from binding to follicle receptors locally - without affecting systemic hormone levels. This makes it relevant for men concerned about Finasteride side effects and for women.
Clinical evidence
Phase III trials showed statistically significant reduction in hair loss progression vs placebo at 24 weeks. The effect is stabilising - slows progression rather than reversing established baldness. It is not a surgical alternative and does not restore significant density in established bald areas.
Clascoterone vs Finasteride
| Factor | Finasteride 1mg | Clascoterone |
|---|---|---|
| Mechanism | Reduces systemic DHT (oral) | Blocks follicle receptors (topical) |
| Efficacy | Higher (85% stabilisation) | Moderate |
| Systemic side effects | Possible 1-2% | Minimal to none |
| Use in women | Contraindicated | Potentially appropriate |
Hair Transplant Turkey | Dr. Arslan Musbeh
